An overview of currently available circulatory assist devices (CADs) is presented with discussion of each system’s optimal use and limitations. Successful application of CAD technology for bridge to transplant or pending recovery of the natural heart requires understanding issues involving team readiness, patient selection, device limitations, patient management, and complications. Currently, many of these devices are in clinical trials with the Food and Drug Administration (FDA). The FDA and the National Institutes of Health play major roles in the ongoing development of this technology. In the near future the learning curve continues as totally implantable systems are used. The ultimate goal is to maintain patients with heart failure on implantable devices with a good quality of life at a reasonable cost
Skip Nav Destination
Article navigation
1 August 1991
Cirdiac Assist Devices|
August 01 1991
Current Perspectives on the Use of Circulatory Assist Devices
Richard G. Smith, MSEE, CCE;
From the Artificial Heart Program, University Medical Center, Tucson, Arizona.
Reprint requests to Richard G. Smith, MSEF., CCE, Artificial Heart Program, University Medical Center, Tucson, AZ 8572–4.
Search for other works by this author on:
Marilyn Cleavinger, MSBME
Marilyn Cleavinger, MSBME
From the Artificial Heart Program, University Medical Center, Tucson, Arizona.
Search for other works by this author on:
AACN Adv Crit Care (1991) 2 (3): 488–499.
Citation
Richard G. Smith, Marilyn Cleavinger; Current Perspectives on the Use of Circulatory Assist Devices. AACN Adv Crit Care 1 August 1991; 2 (3): 488–499. doi: https://doi.org/10.4037/15597768-1991-3014
Download citation file:
Sign in
Don't already have an account? Register
AACN Account
Sign InSign in via your Institution
Sign in via your InstitutionShort-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access
1
Views